Data Insights

MB-105 by March Biosciences for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

MB-105 is under clinical development by March Biosciences and currently in Phase I for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute...

Likelihood of Approval and Phase Transition Success Rate Model - MB-105 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)

Data Insights

MB-105 by March Biosciences for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval

MB-105 is under clinical development by March Biosciences and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - MB-105 in Peripheral T-Cell Lymphomas (PTCL)

Data Insights

MB-105 by March Biosciences for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval

MB-105 is under clinical development by March Biosciences and currently in Phase I for Anaplastic Large Cell Lymphoma (ALCL). According...

Likelihood of Approval and Phase Transition Success Rate Model - MB-105 in Anaplastic Large Cell Lymphoma (ALCL)

Data Insights

MB-105 by March Biosciences for Acute Lymphoblastic Lymphoma: Likelihood of Approval

MB-105 is under clinical development by March Biosciences and currently in Phase I for Acute Lymphoblastic Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - MB-105 in Acute Lymphoblastic Lymphoma

Data Insights

MB-105 by March Biosciences for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval

MB-105 is under clinical development by March Biosciences and currently in Phase I for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. According...

Likelihood of Approval and Phase Transition Success Rate Model - MB-105 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy

Data Insights

MB-105 by March Biosciences for Sezary Syndrome: Likelihood of Approval

MB-105 is under clinical development by March Biosciences and currently in Phase I for Sezary Syndrome. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - MB-105 in Sezary Syndrome

Data Insights

MB-105 by March Biosciences for Non-Hodgkin Lymphoma: Likelihood of Approval

MB-105 is under clinical development by March Biosciences and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - MB-105 in Non-Hodgkin Lymphoma

Data Insights

MB-105 by Mustang Bio for Pancreatic Cancer: Likelihood of Approval

MB-105 is under clinical development by Mustang Bio and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - MB-105 in Pancreatic Cancer